Mitera Biosciences Secures $1.75M to Develop Pregnancy-Inspired Immunotherapies for Autoimmune and Transplant Patients

Mitera Biosciences has emerged from stealth with $1.75 million to develop therapeutics targeting autoimmune diseases and organ transplant rejection, inspired by the immune tolerance mechanisms of pregnancy. The company focuses on a placenta- and thymus-expressed protein to create novel immunotherapies that aim to reduce side effects of current immunosuppressants.